Case report: EGFR-TKI rechallenge after osimertinib-induced interstitial lung disease: a case report and literature review

• Published in: Frontiers in pharmacology Vol. 15; p. 1410684
• Main Authors: Gu, Xiaofei, Zhong, Yonghong, Huang, Huaqiong
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 04.06.2024
• Subjects: epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI); interstitial lung disease (ILD); non-small cell lung cancer (NSCLC); osimertinib; Pharmacology; rechallenge; epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI); interstitial lung disease (ILD); rechallenge; non-small cell lung cancer (NSCLC); osimertinib

Osimertinib, a third-generation tyrosine kinase inhibitor (TKI), has demonstrated significant efficacy in treating non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations. However, EGFR-TKI-induced interstitial lung disease (ILD), a well-known adverse effec...